Cargando…
Budget and health impact of switching eligible patients with atrial fibrillation to lower- dose dabigatran
Objectives: To assess the comparative budget and health impact of lower-dose dabigatran versus reduced doses of apixaban and rivaroxaban in atrial fibrillation (AF) patients eligible for a lower-/reduced-dose due to individual patient characteristics in the Netherlands. Methods: A budget impact mode...
Autores principales: | Fens, Tanja, de Jong, Lisa, Kappelhoff, Bregt, Boersma, Cornelis, Postma, Maarten J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Routledge
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478629/ https://www.ncbi.nlm.nih.gov/pubmed/37675057 http://dx.doi.org/10.1080/20016689.2023.2247719 |
Ejemplares similares
-
Comments on—Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose
por: Heinrich-Nols, Jutta, et al.
Publicado: (2020) -
Cost of dabigatran for atrial fibrillation
por: Gage, Brian F
Publicado: (2011) -
Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands
por: Stevanović, J., et al.
Publicado: (2016) -
Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management
por: Weltermann, A., et al.
Publicado: (2012) -
Comparison of effectiveness and safety between uninterrupted direct oral anticoagulants with and without switching to dabigatran in atrial fibrillation ablation
por: Harada, Masahide, et al.
Publicado: (2020)